12 October 2021: Original Paper
Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation
Chengxin Luo 12CDE , Qingrong Li 12B , Xi Li 3B , Guixian Wu 12B , Xiangtao Huang 12B , Yali Zhang 12B , Yanni Ma 12B , Mingling Xie 12B , Yanni Sun 12B , Yarui Huang 12B , Zhen Huang 12B , Shuangnian Xu 12AEG* , Jieping Chen 12AEG*DOI: 10.12659/AOT.933365
Ann Transplant 2021; 26:e933365
Table 2 Results of univariate and multivariate Cox regression analyses for progression-free survival.
| Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | P | HR (95%CI) | P | |
| Male | 1.99 (0.97–4.09) | 0.061 | ||
| Age >60 | 3.06 (1.34–6.97) | 0.008* | 2.92 (1.27–6.71) | 0.012* |
| BMI | 0.49 (0.12–2.05) | 0.331 | ||
| Lymphoma subtype | ||||
| B-NHL | 1.00 | |||
| T-NHL | 1.34 (0.55–3.25) | 0.519 | ||
| NK/T-NHL | 1.80 (0.54–5.99) | 0.339 | ||
| HL | 0.56 (0.17–1.83) | 0.334 | ||
| ECOG PS 2–3 | 1.33 (0.71–2.52) | 0.376 | ||
| Ann Arbor stage III–IV | 0.95 (0.44–2.07) | 0.901 | ||
| B symptoms | 0.98 (0.51–1.89) | 0.947 | ||
| IPI risk | ||||
| Low | 1.00 | |||
| Low-intermediate | 1.11 (0.51–2.45) | 0.793 | ||
| High-intermediate | 0.99 (0.38–2.62) | 0.987 | ||
| High | 1.99 (0.82–4.80) | 0.127 | ||
| LDH elevation (>240 U/L) | 1.72 (0.92–3.23) | 0.090 | ||
| Bone marrow involvement | 1.64 (0.64–4.22) | 0.304 | ||
| Prior regimens | 1.07 (0.71–1.6) | 0.744 | ||
| 1.00 | ||||
| 5–10 | 0.87 (0.41–1.84) | 0.708 | ||
| ≥10 | 1.77 (0.54–5.88) | 0.348 | ||
| PR or NR | 1.70 (0.89–3.24) | 0.107 | ||
| Disease duration | 1.00 (0.98–1.02) | 0.953 | ||
| Albumin | 3.29 (1.60–6.79) | 0.001* | 3.19 (1.54–6.63) | 0.002* |
| TP | 2.25 (1.07–4.76) | 0.033* | ||
| Globulin level | 0.95 (0.88–1.02) | 0.178 | ||
| Albumin/globulin ratio | 0.87 (0.33–2.28) | 0.781 | ||
| Conditioning regimen | ||||
| BEAM | 1.00 | |||
| BEAC | 1.35 (0.50–3.67) | 0.551 | ||
| CBV | 1.12 (0.41–3.07) | 0.834 | ||
| CHOP-like | 1.21 (0.43–3.40) | 0.712 | ||
| Dose of infused mononuclear cells | 0.96 (0.83–1.11) | 0.599 | ||
| Maintenance therapy | 1.20 (0.63–2.31) | 0.575 | ||
| * | ||||